ATP-binding cassette (ABC) transporters in normal and pathological lung

van der Deen, M; de Vries, EGE; Timens, W; Scheper, RJ; Timmer-Bosscha, H; Postma, DS

Published in: Respiratory Research

DOI: 10.1186/1465-9921-6-59

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date: 2005

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):
van der Deen, M., de Vries, EGE., Timens, W., Scheper, RJ., Timmer-Bosscha, H., & Postma, DS. (2005). ATP-binding cassette (ABC) transporters in normal and pathological lung. Respiratory Research, 6, Article 59. https://doi.org/10.1186/1465-9921-6-59

Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license. More information can be found on the University of Groningen website: https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment.

Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Download date: 02-10-2023
Abstract

ATP-binding cassette (ABC) transporters are a family of transmembrane proteins that can transport a wide variety of substrates across biological membranes in an energy-dependent manner. Many ABC transporters such as P-glycoprotein (P-gp), multidrug resistance-associated protein 1 (MRP1) and breast cancer resistance protein (BCRP) are highly expressed in bronchial epithelium. This review aims to give new insights in the possible functions of ABC molecules in the lung in view of their expression in different cell types. Furthermore, their role in protection against noxious compounds, e.g. air pollutants and cigarette smoke components, will be discussed as well as the (mal)function in normal and pathological lung. Several pulmonary drugs are substrates for ABC transporters and therefore, the delivery of these drugs to the site of action may be highly dependent on the presence and activity of many ABC transporters in several cell types. Three ABC transporters are known to play an important role in lung functioning. Mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene can cause cystic fibrosis, and mutations in ABCA1 and ABCA3 are responsible for respectively Tangier disease and fatal surfactant deficiency. The role of altered function of ABC transporters in highly prevalent pulmonary diseases such as asthma or chronic obstructive pulmonary disease (COPD) have hardly been investigated so far. We especially focused on polymorphisms, knock-out mice models and in vitro results of pulmonary research. Insight in the function of ABC transporters in the lung may open new ways to facilitate treatment of lung diseases.

Introduction

The prime role of the airways (trachea, bronchi, bronchioles and terminal bronchioles) is to conduct air into and out of the lung and to form a first line of defence against undesired constituents of inhaled air. The airways are continuously exposed to pathogens, irritants, pollutants and agents that produce oxidative stress and therefore, the composition of the respiratory tract surface is very important. The upper airways contain specialised cell types such as ciliated cells and mucous secreting goblet cells. The
lower conducting airways (respiratory bronchioles, alveolar ducts and alveolar sacs) participate in gas exchange by diffusion. The alveolar epithelial surface comprises essentially two cell types, the alveolar epithelial type I cell and the cuboidal alveolar epithelial type II cell. Type I cells flatten out and in this way constitute approximately 95% of the total alveolar surface, whereas type II cells are more numerous and produce surfactant [1].

ABC (ATP-binding cassette) transporters are a family of transmembrane proteins that can transport a wide variety of substrates across biological membranes in an energy-dependent manner. They are phylogenetically classified in seven distinct subfamilies of transporters (ABCA to ABCG), which are again divided into subgroups. To date, 48 ABC transporters have been detected in the human body [2,3]. Overexpression of ABC transporters such as P-glycoprotein (P-gp) and the multidrug resistance-associated protein 1 (MRP1) were initially detected in tumour cell lines. Their overexpression is associated with increased efflux of chemotherapeutic drugs such as anthracyclines, epipodophyllotoxins and vinca-alkaloids, and this can result in so-called multidrug resistance (MDR). Many MDR proteins can act as drug efflux pumps, resulting in decreased intracellular concentrations of toxic compounds at the site of action. MRP1 and P-gp expression in the lung have especially been studied in the context of small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Currently we know that ABC transporters are present in virtually every cell of all species and play central roles in physiology. The prominent expression of P-gp and MRP1 in the human lung [4] suggests that these transporters may be pivotal in the protection against endogenous or exogenous toxic compounds entering the lung. The delivery of pulmonary drugs to reach the site of action may also depend on the presence and activity of many ABC transporters [5]. Langmann et al. developed quantitative real-time RT-PCR expression profiling of 47 ABC transporters in 20 different human tissues. Tissues with a barrier function such as lung and trachea were identified to have high transcriptional activity for many ABC transporters [6]. There are already clear proofs of important functions of ABC transporters in the lung. The ABC transporter most widely investigated is the cystic fibrosis transmembrane conductance regulator (CFTR), because mutations in this gene are responsible for the development of cystic fibrosis [7]. Mutations in ABCA1 are causative for Tangier disease [8]. In newborns it was shown that mutations in ABCA3 cause aberrant production of surfactant which can be lethal [9]. The role of altered function of ABC transporters in highly prevalent pulmonary diseases such as asthma or chronic obstructive pulmonary disease (COPD) have hardly been investigated so far [10].

This review aims to give new insights in the possible functions of ABC molecules in the lung in view of their expression in different cell types. Furthermore, their roles in protection against noxious compounds will be discussed as well as the (mal)function in normal and pathological lung. We especially focused on the members of the ABCC subfamily of transporters (to which the MRPs and CFTR belong), the ABCB subfamily (a.o. MDR1/Pgp and MDR3/Pgp) and the ABCA subfamily (a.o. ABCA1 and ABCA3), because these are a selection of the best characterised human transporters and because they have been investigated in human lungs. Results of in vitro studies in pulmonary research are being reviewed and an update will be given about what is known about pulmonary functional changes in ABC transporter knock-out mouse models. In addition, the (potential) effects of polymorphisms in ABC transporters on lung functioning are discussed.

**MDR1/P-gp**

**MDR1 localisation and function**

The *MDR1* (ABCB1) gene is located on chromosome 7q21.12 and encodes for P-gp. P-gp plays a role in cell defence against environmental attacks such as generated by xenobiotics. It transports many hydrophobic substrates and anti-cancer drugs including etoposide, doxorubicin and vinblastine (for review, see [11]) and is mainly apically expressed in organs involved in excretion such as liver and intestine. In the lung, P-gp is expressed at the apical side of ciliated epithelial cells or ciliated collecting ducts, and on apical and lateral surfaces of serous cells of bronchial glands but not in mucus-secreting goblet cells (Figure 1 and 2) (Table 1) [12]. Epithelial cells of the trachea and major bronchi stain strongly while staining of the smaller bronchi is patchy or absent. In addition, P-gp is present in the lateral membranes of normal nasal respiratory mucosa [13]. In human and rat type I alveolar epithelium, P-gp is located at the luminal side whereas freshly isolated type II cells lack P-gp [14]. In another study, pneumocytes did not stain for P-gp [15]. Some antibodies visualised P-gp in endothelial cells of blood vessels (Figure 1) [12,15,16]. In addition, alveolar and peripheral blood monocyte-derived macrophages stained positive but variably for P-gp [4,16,17]. The observed apical epithelial expression may signify that P-gp plays a role in transport of compounds from the interstitium into the lumen. However, the precise function of P-gp in the lung is as yet unknown. Interestingly, P-gp was found to play a role in the regulation of cell volume activated chloride channels and to possess channel activities [18,19]. However, Cl⁻ and K⁺ conductances were not affected by the level of P-gp expression and the physiological role of P-gp in volume-activated chloride currents is still unclear [20-22]. Many lipophilic amines, such as fentanyl, highly accumulate in the lung. It was suggested that P-gp plays a role in the disposition of these pulmonary amine drugs...
Morphisms was studied in tobacco-related lung cancer [23]. Cellular uptake in lung microvascular endothelial cells of fentanyl was inhibited by the P-gp substrate verapamil, but not by the P-gp blocking antibody UIC2. The authors suggested that this results from an inhibition of fentanyl uptake. This is however unlikely, since P-gp is primarily responsible for removal of drugs out of cells.

P-gp mRNA expression was not increased in smokers (n = 11) compared to ex- and non-smokers (n = 7) [12]. Whether P-gp expression levels may play a defensive role towards tobacco-derived agents remains to be investigated.

MDR1 in tumours

High P-gp expression can imply chemotherapeutic resistance due to increased chemotherapeutic drug efflux. In cancer therapy, many attempts have been made to reverse MDR mechanisms. However, in a randomised double-blind trial in 130 SCLC patients no positive effects were seen with the P-gp modulator megestrol acetate in addition to chemotherapeutic drugs, suggesting that levels of P-gp expression in lung tumours were not relevant or that modulation of P-gp activity was not complete in this treatment [24]. Some studies show higher P-gp expression at the invasion front of lung tumours and it was suggested that P-gp expression augments invasion properties of tumour cells [25]. Only two out of 22 NSCLC samples (both adenocarcinomas) stained positive with three P-gp antibodies [15] and no P-gp was detected on pulmonary antibodies [15] and no P-gp was detected on pulmonary carcinoids. Other studies revealed a relation between P-gp and glutathione S-transferase-pi (GST-pi) expression in NSCLC that were exposed in vitro to doxorubicin [26], suggesting that these two factors play a role in doxorubicin resistance. There was also a correlation between current smoking and doxorubicin resistance of NSCLC. Forty-two out of 72 NSCLC smokers expressed P-gp, whereas only two out of 22 tumours of non-smokers were P-gp positive [27].

MDR1 polymorphisms

MDR1 polymorphisms were first described by Hoffmeyer et al. [28] who found a correlation between lower intestinal expression of P-gp and a polymorphism in exon 26. Many single nucleotide polymorphisms (SNPs) have been recognised in the MDR1 gene (see reference [29] for recent review about clinical aspects). The impact of these polymorphisms on lung diseases is still speculative. It was proposed that polymorphisms in the MDR1 gene may have clinical consequences in patients with cystic fibrosis, since MDR1 plays a role in CFTR regulation. Rodents contain two Mdr1 genes, denoted as Mdr1a and Mdr1b. It was shown that Mdr1b mRNA expression in lung parenchyma of outbred rats is very variable and this may also be the case in humans [30]. The possible effects of MDR1 polymorphisms was studied in tobacco-related lung cancer [31]. No clear association was found between the T/T genotype of the C3435T polymorphism and susceptibility to lung cancer in a group of 268 Caucasian men who were current smokers. No relation was found between SNP C3435T in MDR1 and survival in 62 docetaxel-cisplatin-treated NSCLC patients [32]. Immunosuppressive agents such as cyclosporin A and tacrolimus (both calcineurin antagonists) are P-gp substrates. No relation was found of MDR1 G2677T and C3435T genotypes with tacrolimus blood levels in 83 lung transplant patients treated with tacrolimus [33]. Altogether, these data implicate that there is still no clear association between MDR1 polymorphisms and effects on outcome of treatment of lung cancer or lung transplant patients.

MDR1 in animal models

Scheffer et al. detected high P-gp levels in lungs of mouse [4]. In rats, Mdr1a and Mdr1b mRNA expression were highest in the ileum [34]. The Mdr1a expression level in rat lung was 2% of the expression in ileum and expression of Mdr1b was 47% of that in ileum. In mice orally treated with dexamethasone for 24 hours, Mdr1b mRNA expression in lungs was decreased, from which the authors deduce that dexamethasone treatment of lung tumours may reverse MDR [35]. To study the in vivo distribution of P-gp, nude rats were injected with a P-gp overexpressing SCLC cell line (GLC4/Pgp) and with a P-gp negative cell line (GLC4) [36]. P-gp function was visualised with radiolabeled P-gp substrate [11C]verapamil by positron emission tomography (PET) with or without P-gp modulator cyclosporin A. The accumulation of [11C]verapamil was significantly increased by cyclosporin A in brains and GLC4/Pgp tumours in these rats. In all other investigated organs including lungs, the accumulation after cyclosporin A treatment was unaltered. In intact rabbit lung, vascular P-gp kinetics were measured in vivo using the lipophilic amine dye rhodamine 6G (R6G) by measuring R6G in the perfusate during circulation [37]. Inhibition of P-gp function with verapamil or GF120918 resulted in higher accumulation of R6G in lung. It was proposed that the opposite would happen when epithelial P-gp was inhibited because R6G would then be retained in the airspace. We propose another possibility that inhibition of epithelial P-gp will also result in higher R6G accumulation. In that case, R6G transport to the lumen is inhibited and as a compensation mechanism it may be transported back to the interstitial side where it either may be retained in the tissue or subsequently be transported into the circulation. This model could be useful in testing a large variety of pulmonary therapeutic agents, such as corticosteroids and sympathicomimetics that may be substrates for transporters in the lung or modulate their activity. Similar studies were also carried out in perfused rat liver to assess the effect of P-gp modulators on the hepatobiliary system, supporting the usefulness of this approach [38].
Mdr1a/1b (-/-) mice lack both genes encoding for P-gp and these mice seem physiologically normal. The penetration of $[^3]$H digoxin (a P-gp substrate) was higher in brain, ovary and adrenal gland. In the lung tissue of these (-/-) mice [39], the level of $[^3]$H digoxin was rather low compared to other organs. The level was 2.6 times higher in (-/-) mice than in (+/+) mice, but this was not significant. The pharmacokinetics of the central nervous system (CNS) drug amitryptiline (a P-gp substrate) and its metabolites were examined in Mdr1a/1b (-/-) mice by high performance liquid chromatography (HPLC) in several organs. Higher concentrations of these metabolites were measured in the brain of these mice, but not in other examined organs including the lung [40]. Thus, P-gp likely plays a more active role in exporting CNS drugs out of the brain than out of the lung. Another possibility is that other transporters in the lung were capable to efflux these drugs as a compensation mechanism.

**MDR1 in vitro**

Several lung cell culture models have been described for determining P-gp expression and functionality. The immortalised human bronchial epithelial cell line 16HBE14o resembles primary epithelium and was reported to be suitable for drug metabolism studies [41]. In 16HBE14o cells, P-gp was expressed at the apical side. Its functional activity was measured with P-gp substrate rhodamine 123 and its transport was inhibited by verapamil [42]. Two lung cell lines, Calu-3 and A549 cells, were compared for P-gp expression and functionality [43]. The bronchiolar adenocarcinoma cell line Calu-3 is suitable for drug transport studies because these cells form tight junctions in culture, which is not the case for the type II alveolar carcinoma cell line A549. P-gp expression was higher in A549 cells than in Calu-3 cells. However, efflux of rhodamine 123 was higher in Calu-3 cells. This may be explained by additional MRP1 activity in these cells because rhodamine 123 is also an MRP1 substrate [44]. In primary rat alveolar type II cells, Mdr1b mRNA levels increased in a time dependent manner in cultures at day 1, 2 and 3 compared to freshly isolated cells. Mdr1b mRNA was present at low levels and increased after oxygen radical induction with paraquat [45]. P-gp expression was below the detection limit in these cells at time of isolation. In freshly isolated primary human bronchial epithelial cells, P-gp was present and increased after 24 hours paraquat exposure. Rhodamine 123 efflux could be measured in these cells, confirming functional activity of P-gp [45]. These results demonstrate that P-gp is upregulated during stress, both from radical production and from ex vivo culturing or differentiation.

**MDR3/P-gp**

The MDR3/P-gp (ABCB4) gene maps closely to MDR1/P-gp on chromosome 7q21.12 and has high homology with MDR1 although its function is very different. It is involved in phosphatidyl choline transport from the liver into the bile. Its RNA and protein have not been detected in human and mouse lung and trachea [4,6] and it is therefore not expected that MDR3 is present in the lungs.

**MRP1**

**MRP1 localisation and function**

The MRP1 (ABCC1) gene is located on chromosome 16p13.12. Cole et al. discovered in 1992 a non-Pgp mediated MDR mechanism in the human lung cancer cell line H69AR [46]. MRP1 was overexpressed in these cells and it was found that glutathione-, glucuronide-, and sulfate-conjugated organic anions are substrates for MRP1 [47,48]. MRP1 confers resistance to several chemotherapeutic agents including vincristine, daunorubicin and...
methotrexate [49-51]. Physiological substrates for MRP1 are e.g. leukotriene C\textsubscript{4} (LTC\textsubscript{4}) and glutathione disulfide (GSSG) [52]. Interestingly, these substrates play an important role in lung physiology with respect to inflammation and oxidative stress. MRP1 is highly expressed mainly at the basolateral side of human bronchial epithelial cells (Figure 1 and 2) [53]. Ciliated and basal cells have been collected from brushes of main or lobar bronchi. Basal cells stained strongly on the entire circumference of the plasma membrane. Ciliated epithelial cells and mucous cells stained positive at the basolateral membrane but not at the apical membrane. No intracytoplasmic staining was observed. However, strong apical cytoplasmic staining has been detected below the cilia in respiratory columnar epithelial cells in paraffin sections with antibody MRPr1 [4,13,54]. The discrepancy between these findings may be due to different fixation procedures. Basal cells of seromucinous glands of the lungs also stain positive for MRP1 with a higher intensity in the serous area than mucinous cells. Alveolar macrophages are MRP1 positive with variable staining between individual lung samples (Figure 2) [4]. Kool et al. investigated MRP1, 2, 3, 4, and 5 with an RNase protection assay in total lung RNA and found high MRP1, absence of MRP2, low MRP3 and MRP4 and moderate MRP5 gene transcripts [55]. Total RNA was obtained from lung tissue collected during surgery or autopsy. Therefore, the original cell types can not be distinguished in these samples.

Possibly, the high MRP1 expression at the basolateral side of lung epithelium may assist in the clearance of toxins coming from the luminal or interstitial side (back) into the interstitial fluid [56]. Function of MRP1 expression in the lung epithelium, glands and alveolar macrophages may include extrusion of toxic intracellular substances, antioxidant defence or production of LTC\textsubscript{4} as an inflammatory response. Given the fact that MRP1 expression is higher in the lung compared to other solid organs, decreased or increased functional MRP1 expression may have a high impact on development and/or progression of

Table 1: Summary of features of ABC transporters in human lung.

| ABC gene     | Gene location | Functional role or substrates | Linked to disease | Protein expression in lung cells (+ localisation) | References# |
|--------------|---------------|-------------------------------|------------------|---------------------------------------------------|-------------|
| MDR1/P-gp (ABCB1) | 7q21.12       | Drug resistance, Hydrophobic organic cations | Unknown          | Bronchial epithelium (ap), mucinous glands (ap), alveolar type I cells (ap), endothelium\textsuperscript{b} (ap), alv. macroph. | [4,12,14-16] |
| MDR3/P-gp (ABCB4) | 7q21.12       | Phosphatidyl choline          | Unknown          | Absent Bronchial epithelium (ba/la), goblet cells (ba), peripheral epithelial cells\textsuperscript{a} (ba/la), seromucinous glands (ba/la), alv. macroph. | [4]         |
| MRP1 (ABCC1)   | 16p13.12      | Drug resistance, Organic anions (e.g. GSH conjugates, LTC\textsubscript{4}) | COPD?            | Bronchial epithelium\textsuperscript{a} (ap), primary bronchial and peripheral epithelial cells\textsuperscript{b} (in) | [4,53,85]   |
| MRP2 (ABCC2)   | 10q24.2       | Drug resistance, Organic anions | Dubin-Johnson syndrome | Bronchial epithelium\textsuperscript{a} (ap), primary bronchial and peripheral epithelial cells\textsuperscript{b} (in) | [4,85,90]   |
| MRP3 (ABCC3)   | 17q21.33      | Drug resistance, Organic anions | Unknown          | Primary bronchial and peripheral epithelial cells\textsuperscript{a} (ba/la) | [85]        |
| MRP4 (ABCC4)   | 13q32.1       | Nucleoside analogues, Prostaglandin E\textsubscript{1}, E\textsubscript{2} | Unknown          | Primary bronchial and peripheral epithelial cells\textsuperscript{a} (in) | [85]        |
| MRP5 (ABCC5)   | 3q27.1        | Nucleoside analogues, Hyaluron | Unknown          | Primary bronchial and peripheral epithelial cells\textsuperscript{a} (in) | [85]        |
| MRP6 (ABCC6)   | 16p13.12      | Unknown                       | Pseudoxanthoma elasticum | Unknown                        |             |
| MRP7 (ABCC10)  | 6p21.1        | Conjugated steroids,          | Unknown          | Unknown                        |             |
| MRP8 (ABCC11)  | 16q12.1       | Nucleoside analogues, bile acids | Unknown          | Unknown                        |             |
| MRP9 (ABCC12)  | 16q12.1       | Unknown                       | Unknown          | Unknown Bronchial epithelium (ap), seromucinous glands (ap), Clara cells\textsuperscript{a}, Alv. type I cells\textsuperscript{a} | [117-120]   |
| CFTR (ABCC7)   | 7q31.31       | Chloride ion channel          | Cystic fibrosis  | Bronchial epithelium (ba/la), endothelium, seromucinous glands | [4]        |
| BCRP (ABCG2)   | 4q22          | Drug resistance, Protection food toxins | Unknown          | Bronchial epithelium (ba/la), endothelium, seromucinous glands | [4]        |
| ABCA1          | 9q31.1        | Cholesterol and phospholipids | Tangier disease  | Alv. type II cells              | [151]       |
| ABCA3          | 16p13.3       | Surfactant secretion          | Surfactant deficiency | Alv. type II cells              | [155]       |

\textsuperscript{a}Cellular localisation: ap, apical; ba, basal; la, lateral; in, intracellular; alk, alveolar; macroph., macrophages; \textsuperscript{b}References are mentioned that demonstrate protein localisation histologically; \textsuperscript{c}Conflicting results exist in literature.
lung diseases and protection against air pollution and inhaled toxic substances such as present in cigarette smoke [10].

**MRP1 in tumours**

Using mRNA in situ hybridisation Thomas et al. [57] detected high MRP1 expression in normal epithelium whereas the major component of the tumour epithelium showed a negative hybridisation signal. However, MRP1 transcript expression at the invasive front of the lung tumours was consistently stronger and particularly strong in areas with lymphatic or blood vessels. In addition, endothelial cells and lymphocytic infiltrates stained strongly positive for MRP1. These results may indicate a role of MRP1 in invasion or in mitotic activity. In a recent study, all 102 NSCLC tumours were MRP1 positive. In addition, the level of expression was 3-fold higher in DNA-aneuploid cells compared to normal bronchial and carcinomatous DNA-diploid cells [58]. This was associated with more frequent gain of chromosome 16 where the MRP1 gene is located. Overexpression of MRP1 may therefore be an important factor of intrinsic resistance to chemotherapy in NSCLC. High MRP1 expression can also result in increased apoptosis as shown by experiments with verapamil in MRP1 transfected baby hamster kidney-21 (BHK-21) cells [59]. Verapamil acts as an apoptogen in these cells when compared to MRP1 negative cells or mutant MRP1 transfected control cells. This was accompanied by depletion of intracellular GSH due to transport of GSH by MRP1. Indeed, addition of extracellular GSH prevented cell death. This mechanism may be valuable for treatment of MRP1-positive tumours.

**MRP1 in non-malignant diseases**

Cigarette smoking is the principle risk factor for the development of COPD. Our preliminary results indicate that MRP1 expression is diminished in bronchial epithelium of COPD patients (ex-smokers) and that lower expression is related to worse lung function [10]. In addition, bronchial MRP1 expression was higher during smoking than after one year of smoking cessation (Van der Deen et al., submitted). The expression of MRP1 measured with RT-PCR was similar in lungs of smokers and a combined group of ex- and non-smokers, suggesting that current smoking does not affect MRP1 gene expression [53]. This was semi-quantitatively analysed and the power of this study was rather low (smokers n = 13 and ex- or non-smokers n = 8). Cigarette smoke extract is a complex mixture of many substances. One of these is nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNK), a carcinogenic nitrosamine. NNK is converted intracellularly in NNAL-O-glucuronide which is transported by MRP1 in the presence of glutathione (GSH) [60]. Thus, functional activity of MRP1 in the lung may play an

![Figure 2](http://respiratory-research.com/content/6/1/59) Immunohistochemical staining of ATP-binding cassette proteins in human lung. A. apical expression of P-gp in bronchial epithelium (COPD patient; frozen section, antibody C219), B. basolateral expression of MRP1 in bronchial epithelium (COPD patient; antibody MRPr1), C. MRP1 expression in bronchoalveolar lavage cells (healthy individual; antibody MRPr1). Lu, lumen. Scale bar = 25 µM.
important role in the antioxidant defence against toxic compounds generated by cigarette smoke.

**MRP1 polymorphisms**

Polymorphisms of the *MRP1* gene or in regulatory genes may influence function of MRP1 in the lung. *MRP1* has been screened for genetic variations and several mutations have been found in the *MRP1* gene in the human population [61,62]. Ethnic differences for MRP1 expression were observed between Caucasian and Japanese subjects but the clinical consequences have to be determined to date [63,64]. In preclinical models, a single mutation in the *MRP1* gene can result in loss of function of some, but not all, MRP1 substrates [65] which implies that potentially minor differences in the *MRP1* gene may result in aberrant functional capacities of the MRP1 protein. A low frequency (<1%) naturally occurring mutation in *MRP1* was related to functional differences in organic anion transport and drug resistance [66]. Therefore, some individuals could be more susceptible to a set of xenobiotics than others.

**MRP1 in animal models**

Scheffer et al. detected, besides P-gp, high levels of Mrp1 in lungs of mice [4]. *Mrp1* (-/-) mice develop normally [67]. Viability, fertility, and a range of histological, hematological, and serum-chemical parameters were similar in *Mrp* (+/+) and *Mrp* (-/-) mice. However, *Mrp1* (-/-) mice are hypersensitive to exposure to several drugs e.g. etoposide, resulting in loss of body weight and death [56,67,68]. In Mrp1 deficient mice there were no gross abnormalities in lungs and other tissues after treatment with the chemotherapeutic drug etoposide-phosphate, but abnormal mucous production was seen around the mouth. Further examination of tissues showed that these mice suffered from oropharyngeal toxicity [56]. In *Mrp1* (-/-) mice, GSH levels were elevated in e.g. lung, kidney, heart, testes and skeletal muscle. In organs that express little MRP1, such as the liver and small intestine, GSH levels were unchanged [67,69]. The increase in GSH was not related to increased levels of gamma-glutamylcysteine synthetase (γ-GCS), the rate-limiting enzyme for production of the tripeptide GSH. This suggests that MRP1 plays a role in GSH metabolism because MRP1 expression determines cellular GSH levels which is γ-GCS independent. In liver tissue, Mrp2 and Mrp5 mRNA levels were increased in *Mrp1* (-/-) mice compared to wild-type mice, probably due to a compensation mechanism. Mdr1a and Mrp3 levels were unchanged in these animals. Unfortunately, lung tissue was not examined [69]. *Mrp1* (-/-) mice showed impaired inflammatory responses accompanied by a decreased LTC4 excretion by leukotriene producing cells [67,68]. The outgrowth of *Mycobacterium tuberculosis* was enhanced in *Mrp1* (-/-) mice, but there was no difference in survival compared to wild-type mice [70]. Strikingly, Schultz et al. [71] observed that the survival of *Mrp1* (-/-) mice inoculated with *Streptococcus pneumoniae* was better than of wild-type mice. This was accompanied by a lower LTC4 concentration but a higher LT B4 level in bronchoalveolar lavage fluid (BALF). Treatment with an LT B4 antagonist abolished the positive effect on survival rate. Altering MRP1 function may therefore be a target for further studies on treatment of pneumonia. Interestingly, LT B4 levels are also elevated in sputum and exhaled breath condensate of COPD patients [72,73]. This is thought to result from a higher amount of neutrophils present, yet also lower functional MRP1 expression may play a role, according to the observations in *Mrp1* (-/-) mice [10,71]. The pulmonary and hepatic carcinogen aflatoxin B1 (a mycotoxin) and its GSH conjugate are MRP1 substrates in vitro [74]. MRP1 may therefore play an important role in detoxification of aflatoxin B1 in the lung. No difference in occurrence of lung tumours (and liver tumours) 12 months after an 8 week exposure to aflatoxin B1 was observed in *Mrp1* (-/-) and wild-type mice [75]. This observation may be explained by differences in exposure time compared to humans (who may be chronically exposed for many years) or by redundancy of other ABC transporters in knock-out mice to export aflatoxin B1 and its conjugates.

NRF2 (nuclear factor-E2 p45-related factor), a transcription factor for many genes that play a role in antioxidant defence and detoxification processes, was recently identified as a transcription factor for MRP1 [76]. Interestingly, the onset of cigarette smoke-induced emphysema was earlier and the extent of emphysema was more severe in *Nrf2* (-/-) mice as compared to wild-type mice [77]. The number of inflammatory cells, mainly consisting of macrophages, in bronchoalveolar lavage fluid and lung tissue was higher in *Nrf2* (-/-) mice, accompanied by more extensive apoptosis of endothelial cells and alveolar type II cells. Forty-five Nrf2-dependent protective genes were induced by smoke exposure in wild-type mice compared to knock-out mice as measured with microarray analysis. Regrettably, *Mrp1* was not present on this gene expression array. Similar smoke exposure experiments with *Mrp1* (-/-) mice would be interesting to investigate if these mice are also more susceptible to develop emphysema. Three polymorphisms were identified in the promotor region of *NRF2* in healthy individuals (n = 81) and in patients with COPD (n = 87) and sytemic lupus erythematosis (n = 51) [78]. There was no relation between these polymorphisms and risk of these diseases, but the power of this study was rather low.

*Mdr1a*/*1b* (-/-)/*Mrp1* (-/-) triple knockout (TKO) mice are indistinguishable from wild-type mice under normal physiological conditions [79,80]. Intravenous injection of [3H]etoposide in TKO mice resulted after 4 hours in a...
higher accumulation in brown adipose tissue, colon, urogenital tract, salivary gland and heart when compared to Mdr1a/1b (-/-) mice. The accumulation of [3H]etoposide in lung did not increase [79]. Accumulation of [3H]vincristine was 26-fold higher in lungs of weaning TKO mice compared to adult TKO mice, 4 hours after a single dose intraperitoneal injection [81]. In TKO compared to wild-type mice, [3H]vincristine was 82.7 and 5.8-fold increased in respectively weaning and adult mice after 4 hours in this experimental setting. Eight hours post-injection, these ratios were 33 and 51.1. Thus, accumulation of vincristine is both time and age-related. In another study, toxicity of the chemotherapeutic drugs vincristine and etoposide was examined [80]. Compared to wild-type mice, [3H]etoposide was not further examined in TKO compared to wild-type mice. Lung tissue was not further examined in TKO compared to wild-type mice after 4 hours in this experimental setting. Eight hours post-injection, these ratios were 33 and 51.1. Thus, accumulation of vincristine is both time and age-related. In another study, toxicity of the chemotherapeutic drugs vincristine and etoposide was elevated in TKO mice (respectively 128-fold and 3–5 fold) compared to wild-type mice. Lung tissue was not further examined [80].

**MRP1 in vitro**

MRP1 overexpression was first described in the human lung cancer cell line H69AR [46]. The human SCLC cell line GLC4/ADR, which displays multiple copies of the MRP1 gene, is often used to study MRP1 function [47]. The lung cell line Calu-3 (from bronchiolar adenocarcinoma/glandular origin) has been reported to express MRP1 basolaterally and has functional MRP1 activity. It may serve as a good model for in vitro analysis of transport activities [44]. Besides P-gp, MRP1 protein was present in freshly obtained primary human bronchial epithelial cells. Efflux of MRP1 substrate carboxy-dichlorofluorescein could be measured in these cells and was inhibited by MRP modulator MK571 [45]. In contrast to upregulation of P-gp, epithelial cells did not respond with MRP1 upregulation to parquat and MRP1 levels were stable in time until 12 weeks, but highly increased after 18 weeks cultivating. An interesting observation was made by Bandi et al. [82] who incubated the airway epithelial cell line Calu-1 with budesonide, an anti-asthma drug. MRP1 expression decreased after 7 and 14 days incubation with budesonide (10 µM) but not at day 1 and 4. MRP1 function was also diminished after 14 days incubation with increasing amounts of budesonide (1, 10 and 100 µM). It was therefore proposed that budesonide could be used as a chemosensitiser in lung tumours. The immortalised bronchial epithelial cell line 16HBE14o- expresses high MRP1 protein levels and activity [83]. MRP1 activity, but not P-gp, was blocked by incubation with cigarette smoke extract. Thus, the expression of MRP1 in human lungs may contribute to the decrease in the accumulation of toxic inhaled substances present in cigarette smoke to protect against pulmonary diseases such as lung cancer or COPD. It was shown that benzo [α]pyrene (B [α]P), a polycyclic aromatic hydrocarbon that is a.o. present in cigarette smoke and car exhaust fuels, increased the efflux of monochlorobimane GSH conjugate (mBCl-SG, which is an MRP substrate) out of primary rabbit alveolar type II cells [84]. This was explained by an increase in GSH levels. MK571 reduced the efflux of mBCl-SG, suggesting that the transport was MRP-mediated. Surprisingly, the transport direction of this substrate was higher to the apical than to the basolateral compartment. This may imply that MRP1 (or other MRPs) is apically located in alveolar type II cells in contrast to the basolateral location that is usually reported for MRP1, or that another transporter is responsible for this unexpected result. MRP1-5 expression was studied in primary human lung cell cultures and in A549 cells [85]. MRP1 and MRP3 expression were membrane-associated whereas MRP2, 4, and 5 were located in intracellular structures in primary cells (both bronchial and peripheral epithelial cells). In A549 cells, all transporters were expressed in the cellular membrane. The fluorescent microscopic pictures, however, did not precisely show the exact cellular localisation and in several cases, the Golgi apparatus also seems to stain beside the cellular membrane.

**MRP2**

**MRP2 localisation and function**

MRP2 (ABCC2) is located on chromosome 10q24.2 and is also named the canalicular multispecific organic anion transporter (cMOAT) in the liver [86]. MRP2 and MRP1 share very similar substrate specificities. High affinity endogenous substrates for MRP2 include amphiphilic anions, such as LTC$_4$ [87,88]. and bilirubin glucuronosides [89,90]. Data on the presence of MRP2 protein in the lung are conflicting. Only one out of three antibodies stained positive at the apical side in bronchial epithelium (Figure 1) [4,90]. If MRP2 is expressed apically, it could be involved in transport of noxious compounds into the lumen of the lung.

**MRP2 in animal models**

There are several rat strains that have a mutation in Mrp2/cMOAT and the phenotypes resemble that of the human Dubin-Johnson syndrome, a disease in which MRP2 is mutated. Examples are the GY/TR rat [91] and the Eisai hyperbilirubinemic rat (EHBR) [92]. Subjects with the Dubin-Johnson syndrome and also Mrp2 deficient rats display jaundice and have impaired organic anion transport. Recently, it was shown that deficient Mrp2 function in EHBR rats was compensated by upregulation of Mrp3 in liver and kidney [93]. Mrp2 (-/-) mice have not been described. There are no reports in the literature of pulmonary malfunction in rats or humans with defects in the MRP2 gene.

**MRP3**

The MRP3 (ABCC3) gene is the closest MRP1 homologue [94] and is located on chromosome 17q21.33. It is involved in resistance against the anti-cancer drugs etoposide, teniposide and at higher concentrations also to
methylotrexate [95]. MRP3 is located in basolateral plasma membranes of liver, adrenals, pancreas, kidney, gut and gallbladder. The physiological function of MRP3 is still unknown but its cellular localisation and the information on substrates implies a role for MRP3 in transport of organic anions from the liver into the blood, especially when secretion into bile is being blocked [96]. MRP3 protein and RNA was not detected in bronchial epithelium [4,96]. However, data in literature are conflicting and preliminary unpublished results indicate that Mrp3 is present in mouse lung. As already mentioned in the discussion on Mrp1, primary epithelial cells (of bronchial and peripheral origin) and A549 cells stain positive for MRP3 (Figure 1) [85]. MRP3 mRNA was measured by quantitative RT-PCR in normal lung and lung tumours. MRP3 transcript levels were related to exposure to vincristine, etoposide and platinum drugs in lung tumours [97,98].

**MRP4 and MRP5**

MRP4 (ABCC4) and MRP5 (ABCC5) genes map to 13q32.1 and 3q27.1 respectively. MRP4 protein is highly expressed in the kidney and prostate and MRP4 mRNA is present in the lung [55,99]. MRP5 mRNA is ubiquitously expressed, mainly in brain and skeletal muscle and also in the lung [6,55]. Primary epithelial cells (of bronchial and peripheral origin) and A549 cells stain positive for MRP4 and 5 (Figure 1) [85]. The substrate specificities of these two transporters differ from the other transporters of the ABCC family, i.e. they transport a variety of nucleoside analogues. The physiological role of both proteins is still unknown but they can serve as an efflux pump of the nucleosides cAMP and cGMP at low affinity, likely in a GSH independent manner [100-103]. Interestingly, AMP levels in lungs of asthma and COPD patients are elevated and independent manner [100-103]. Interestingly, AMP levels in lungs of asthma and COPD patients are elevated and independent manner [100-103]. AMP levels in lungs of asthma and COPD patients are elevated and independent manner [100-103]. AMP levels in lungs of asthma and COPD patients are elevated and independent manner [100-103]. AMP levels in lungs of asthma and COPD patients are elevated and independent manner [100-103].

**CFTR**

**CFTR localisation and function**

CFTR (ABCC7) is located on chromosome 7q31.31. CFTR is the only member of the ABC superfamily which is not an active transporter. It functions as a chloride channel and in normal human airway tissue CFTR is highly expressed at the luminal side in serous cells of the submucosal glands. In addition, it is restricted to the apical membrane domain of well-differentiated epithelial cells such as ciliated cells, and probably also non-ciliated Clara cells and alveolar type I cells (Figure 1) [117-120]. CFTR is also expressed in normal nasal respiratory mucosa [13].

**CFTR in cystic fibrosis**

Mutations in the CFTR gene can cause cystic fibrosis [7] and are associated with abnormal Cl- and Na+ ion transport in several tissues including the lungs, pancreas, gastrointestinal tract, liver, sweat glands and male reproductive organs. Although the normal expression of CFTR in the lung is lower compared to tissues such as the intestine and pancreas, its function in the lung is of major importance. The most frequent mutation in this gene is the delta F508 mutation which leads to cystic fibrosis. Defective CFTR function can cause viscous secretions in the lungs which leads to chronic inflammation with acute exacerbations by impaired mucociliary clearance. There are major risks for colonisation with *Pseudomonas aeruginosa* which leads to pneumonia and respiratory insufficiency [121]. Besides abnormal CFTR localisation and expression in cystic fibrosis, also in non-cystic fibrosis air-
way tissue CFTR can be abnormally expressed in remodelled or dedifferentiated epithelium [122,123], whereas in delta F508 CFTR epithelial cells there may be a normally processed CFTR [120,124]. The regulation and transport function of CFTR are dependent of the state of differentiation and polarisation of epithelial cell cultures [125,126]. Dedifferentiation with hyperplasia or metaplasia was associated with an intracellular localisation or absence of CFTR protein [122]. Hurbain et al. [127] analysed MRP1-5 transcript levels in nasal respiratory cells from cystic fibrosis patients with homozygous delta F508 mutation. Surprisingly, low MRP1 levels were associated with more severe disease and in addition, MRP1 levels were related to cAMP-independent chloride transport suggesting that MRP1 regulates another chloride channel in the apical membrane. CFTR function is cAMP regulated [121], and therefore, MRP4 or MRP5 activity may play a role in regulation of CFTR, since these proteins transport cAMP. Another study showed that CFTR function is blocked by two MRP substrates (taurilithocholate-3-sulphate and beta-estradiol) [128]. This implies that these two substances are also substrates for CFTR, or that CFTR and MRP proteins possess similar anion binding sites. Bebok et al. showed that nitric oxide (NO) and reactive oxygen nitrogen species (RONS) decrease wild-type CFTR protein levels in airway epithelial cell monolayers [129]. Natural sources of NO and RONS are activated in alveolar and interstitial macrophages [130,131], neutrophils [132], alveolar type II cells [133,134], and airway epithelial cells [135]. In this view, CFTR function may be important in pulmonary infections and in the effect of oxidative stress generated by e.g. cigarette smoke.

**CFTR in animal models**

Cftr knock-out mice show reduced viability in contrast to most other ABC transporter knock-outs which are viable and fertile. Trezise et al. developed Cftr knock-out mice that have a severe cystic fibrosis phenotype accompanied by a lack of Cftr-related chloride conductance in e.g. tracheal epithelium [136,137]. They found that the P-gp mRNA level was four-fold increased in intestines of neonatal and 3- to 4-week-old Cftr knock-out mice compared to littermates of the same age. However, in 10-week-olds mice P-gp levels were three-fold decreased. Apparently, a reduction or loss of Cftr function influences P-gp expression.

**CFTR in vitro**

The Calu-3 cell line, which has properties from serous cells of the pulmonary submucosal glands, is often used to study function and expression of CFTR [129,138]. It was demonstrated in Calu-3 cells that CFTR mRNA expression is downregulated after ouabain incubation whereas P-gp expression was upregulated [139]. The bronchial epithelial cell line 16HBE14o- is also invaluable in CFTR research [129,140]. In wild-type and mutant CFTR expressing Sf9 insect cells, it was demonstrated that besides chloride transport, another function of CFTR is transport of GSH in a nucleotide-dependent manner [141]. This observation suggests that CFTR plays a role in the control of oxidative stress. Indeed, several studies in patients, mice and cell lines have shown that GSH levels are lower in case of defective CFTR function.

**BCRP**

**BCRP localisation and function**

BCRP (ABCG2) is the breast cancer resistance protein (BCRP), located on chromosome 4q22. BCRP is a half-transporter that probably acts as a homo- or heterodimer [142] and is involved in resistance against toxins and several chemotherapeutic agents (e.g. mitoxantrone and topoisomerase 1 inhibitors) [143,144]. Protein levels of BCRP in the lung are lower than P-gp and MRPl but distinct in the epithelial cell layer and in seromucinous glands (Figure 1) [4]. BCRP was absent in alveolar macrophages, suggesting that BCRP does not play a major role in innate inflammatory responses in the lung. Small endothelial capillaries also stain positive for BCRP, thus BCRP may protect the lungs against noxious compounds that enter systemically.

**BCRP in tumours**

In a study of untreated solid lung tumours, i.e. squamous cell carcinoma (n = 5), adenocarcinoma (n = 2) and SCLC (n = 3), most cases expressed moderate or strong BCRP [145]. In addition, higher BCRP expression in blood vessels was observed than in vessels of the surrounding tumour, indicating that BCRP may play a role in tumour angiogenesis. In 72 cases of advanced NSCLC, BCRP expression, but not P-gp, MRPl, MRP2 and MRP3, predicted poor clinical outcome [146].

**BCRP in animal models**

Bcrp knock-out mice do not display any abnormalities compared to wild-type mice under normal conditions, except for the colour of their bile which is red instead of yellow on certain diets [147]. However, these mice appear to be extremely sensitive to the phototoxin pheophorbide A, showing that BCRP is important to protect against toxic components. Abnormalities of lungs in Bcrp (-/-) mice have not been reported thus far. Recently, Bcrp1 (Bcrp in the mouse is also called Bcrp1) localisation in the lung of 4- to 8-week old C57Bl/6j mice was studied to identify lung stem cells. These cells possess high activity of efflux of Hoechst dye that is transported by Bcrp1 [148]. In peripheral blood and bone marrow, cells with side population activity represent BCRP positive (haematopoietic) stem cells and this might also be the case for side population cells in the lungs. Indeed, Bcrp1 (-/-) mice did not display side population cells as shown by Hoechst dye that is transported by Bcrp1 [148].
staining of lung digests. In paraffin-embedded tissue sections, Bcrp1 was restricted to smooth muscle cells (of both arteries and airways) and a subpopulation of unidentified round cells in the alveolar space but not detectable in endothelial or epithelial cells. BAL cells of mice were Bcrp1 positive, but did not display side population (SP) activity [148]. Clara cells, a nonciliated bronchiolar epithelial cell type, were also phenotypically described to possess stem cell characteristics [149]. Further investigation is required to identify the stem cell pool in the lung in relation to expression of ABC transporters. Repairing and replacing lost lung tissue is a research area of promising therapeutic possibilities [150].

ABCA1
The ABCA1 gene is mapped to chromosome 9q31.1. It is the causative gene in the development of Tangier disease, a disorder of cholesterol transport [8]. The ABCA1 protein controls transport of cholesterol and phospholipids to apolipoprotein 1 (apoA-1) in alveolar type II cells (Figure 1). Using the siRNA technique for ABCA1, it was shown that ABCA1 is involved in basolateral transport of surfactant that is activated by oxysterol [151]. Abca1 knockout mice show increased concentrations of cholesterol precursors in lung, plasma, intestine and faeces [152]. It was demonstrated that there were major morphologic abnormalities in lungs of these mice, increasing with age. In 30% of 18 months old mice, lung parenchyma was affected. Lesions were characterised by foamy type II pneumocytes with aberrant lamellar bodies, intraalveolar macrophages and cholesterol clefts [153]. In addition, ABCA7, a close homologue of ABCA1 was also found to be highly expressed in mouse lung tissue by Western blot analysis [154].

ABCA3
The ABCA3 gene is located on chromosome 16p13.3. The function of this ABC transporter has not been studied in detail but ABCA3 protein is present in lamellar bodies in human lung alveolar type II cells (Figure 1). Langmann et al. performed quantitative RT-PCR in 20 human tissues and found ABCA3 to be expressed restrictively in the lung [6]. In a recent study in cell lines, an association was found between lung cancer and ABCA3 (and also ABCA2) gene expression by means of quantitative RT-PCR [108].

The high expression of ABCA3 in alveolar type II cells suggests that ABCA3 may play a role in surfactant regulation [155]. Surfactant is important to lower the surface tension in the air-liquid interphase in alveoli. Indeed, in patients with surfactant deficiency and with severe neonatal lung disease it was demonstrated that the ABCA3 gene was frequently mutated [9]. ABCA3 mutations were found in 16 out of 21 patients, but polymorphisms (SNPs) were not found. One mutation was not fatal but was associated with a chronic lung disorder in a 6-year old patient. Other mutations turned out to be fatal and these patients died shortly after birth. Electron micrographs of tissue of patients with surfactant deficiency showed abnormal dense and small lamellar bodies. It was suggested that ABCA3 plays a role in phospholipid metabolism, since it closely resembles ABCA1 and ABCA4 that are known to transport phospholipids.

Conclusion
Little is known about the function of ABC transporters that are expressed in the lung although their overall expression is very high compared to many other organs [6]. This review shows that ABC transporters in the lung are not only relevant for relatively rare diseases such as cystic fibrosis, Tangier disease and surfactant deficiency. Preliminary data indicate that MRP1 expression is lower in COPD patients than in healthy controls. Mutations and polymorphisms in ABC transporters may have important clinical consequences for development of lung diseases. However, overlap in substrate specificities may be compensatory in cases of malfunction of one (or more) transporter(s). Given the complexity of lung architecture, research on detailed cellular processes is difficult but challenging. Several ABC transporter deficient animal models have been developed that are of great value to study the role of these proteins. To date, exposure to cigarette smoke has never been tested in ABC transporter deficient animal models and would potentially give interesting information about the role of ABC transporters in protection against inhaled toxic substances such as present in tobacco smoke. Cell line models have been used to study transport processes and pulmonary drug metabolism. The delivery of pulmonary drugs to the site of action is probably highly dependent on the presence and activity of many ABC transporters in several cell types in the lung. The first barrier after inhalation is the pulmonary epithelium and transporters in the pulmonary endothelium may be critical for the delivery of intravenously or orally administered drugs. Insight in the function of ABC transporters in the lung may open new ways to facilitate treatment of lung diseases.

Abbreviations
ABC = ATP-binding cassette
AMP = adenosine monophosphate
BALF = bronchoalveolar lavage fluid
B[a]P = benzo [a]pyrene
BCRP = breast cancer resistance protein
cAMP = cyclic adenosine monophosphate
CFTR = cystic fibrosis transmembrane conductance regulator

cGMP = cyclic guanosine monophosphate

cMOAT = canalicular multispecific organic anion transporter

CNS = central nervous system

COPD = chronic obstructive pulmonary disease

EHBR = Eisai hyperbilirubinemic rat

γ-GCS = gamma-glutamylcysteine synthetase

GSH = glutathione, reduced form

GSSG = glutathione disulfide; oxidized glutathione

GST = glutathione S-transferase

HPLC = high liquid performance chromatography

LTC₄ = leukotriene C₄

LTD₄ = leukotriene B₄

MDR = multidrug resistance

MRP = multidrug resistance-associated protein

NSCLC = non-small cell lung cancer

NNAL = nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol

NNK = nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butaneone

NO = nitric oxide

NRF2 = nuclear factor-E2 p45-related factor

P-gp = P-glycoprotein

R6G = rhodamine 6G

RONS = reactive oxygen nitrogen species

RT-PCR = reverse transcriptase-polymerase chain reaction

SCLC = small cell lung cancer

SNP = single nucleotide polymorphism

TKO = triple knock-out mice

Competing interests

The author(s) declare that they have no competing interests.

Authors' contributions

MD mainly drafted the manuscript, EV, WT, RS, HT and DP helped to draft the manuscript. All authors read and approved the final manuscript.

Acknowledgements

This work was supported by a grant from the Netherlands Asthma Foundation (NAF97.35) and the "Stichting Astma Bestrijding" (SAB).

References

1. Crapo JD, Barry BE, Gehr P, Bachofen M, Weibel ER: Cell number and cell characteristics of the normal human lung. Am Rev Respir Dis 1982, 125:740-745.

2. Dean M, Hamon Y, Chimini G: The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res 2001, 42:1007-1017.

3. Muller M: Human ABC-transporters. [http://nutrigene.4t.com/humanabc.htm].

4. Scheffer GL, Pijnenborg AC, Smis EF, Muller M, Postma DS, Timens W, van der Vlies EG, Scheper RJ: Multidrug resistance related molecules in human and murine lung. J Clin Pathol 2002, 55:332-339.

5. Hamilton KO, Yazdanian MA, Audus KL: Contribution of efflux pump activity to the delivery of pulmonary therapeutics. Curr Drug Metab 2002, 3:1-12.

6. Langmann T, Maurer R, Zahn A, Moehle C, Probst M, Stremmel W, Schnitz G: Real-time reverse transcription-PCR expression profiling of the complete human ABC-binding cassette transporter superfamily in various tissues. Clin Chem 2003, 49:230-238.

7. Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, Zielenkiewicz J, Lok S, Plavsic N, Chou JL: Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989, 245:1066-1073.

8. Brooks-Wilson A, Maricel M, Clee SM, Zhang LH, Roomp K, van Dam M, Yu L, Brewer C, Collins JA, Molhuizen HO, Loubser O, Ouette BF, Fichter K, Ashbourne-Excoffon KJ, Sensen CW, Scherer S, Mott S, Denis M, Martindale D, Frohlich J, Morgan K, Koop B, Pimstone S, Casale TJ, Hayden MR: Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet 1999, 22:336-345.

9. Shulenin S, Nogee LM, Annilo T, Wert SE, Whitsett JA, Dean M: ABCA3 gene mutations in newborns with fatal surfactant deficiency. N Engl J Med 2004, 350:1296-1303.

10. van der Deen M, Marks H, Muller M, Postma DS, Schefer G, Scheper RJ, Smis EF, Timens W, de Vries EG: Diminished expression of Multidrug Resistance-associated Protein 1 (MRP1) in bronchial epithelium of COPD patients [abstract]. Am J Respir Crit Care Med 2003, 167:A397.

11. Gottesman MM, Fojo T, Bates SE: Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002, 2:48-58.

12. Lechapt-Zalone M, Hurbain I, Lacave C, Commo F, Urban T, Antoine M, Milleron B, Bernaudin JF: MDR1-Pgp 170 expression in human bronchus. Eur Respir J 1997, 10:1837-1843.

13. Wioland MA, Fleury-Feith J, Corlieu P, Commo F, Monceaux G, Lacau-St-Guily J, Bernaudin JF: CFTR, MDR1, and MRP1 immunolocalization in normal human nasal respiratory mucosa. J Histochem Cytochem 2000, 48:115-122.

14. Campbell L, Abulroj AN, Kandalaf AE, Plummer S, Hollins AJ, Gibbs A, Gumbleton M: Constitutive expression of p-glycoprotein in normal lung alveolar epithelium and functionality in primary alveolar epithelial cultures. J Pharmacol Exp Ther 2003, 304:441-452.

15. Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR, Melamed MR: Expression of the multidrug resistance gene product (P-
glutathione) in human normal and tumor tissues. J Histochem Cytochem 1990, 38:1277-1287.

16. Malina J, Kalken CK, Kears S, Broxterman HJ, Scheffer G, Kuiper CM, Tsuuro T, Lankelma J, Meijer CJ, Pinedo HM: Distribution of multi-drug resistance-associated P-glycoprotein in normal and neoplastic human tissues. Analysis with 3 monoclonal antibodies recognizing different epitopes of the P-glycoprotein molecule. Ann Oncol 1990, 1:54-64.

17. Puddu P, Fais S, Luciani F, Gherardini G, Dupuis ML, Romagnoli G, Ramoni C, Cianfriglia M, Gessani S. Interferon-gamma up-regulates expression and activity of P-glycoprotein in human peripheral blood monocyte-derived macrophages. Lab Invest 1999, 79:299-1309.

18. Valverde MA, Diaz M, Sepulveda FV, Gill DR, Hyde SG, Higgins CF: Volume-regulated chloride channels associated with the human multidrug-resistance P-glycoprotein. Nature 1992, 355:830-833.

19. Hoogsteden HC, Higgins CF, Valverde MA, Mintenig GM, Sepulveda FV: Separation of drug transport and chloride channel functions of the human multidrug resistance P-glycoprotein. Cell 1992, 71:23-32.

20. Higgins CF: P-glycoprotein and cell volume-activated chloride channels. J Bacteriol 1995, 177:63-70.

21. Kunzelmann K, Slotkii IK, Klein P, Koslowsky T, Aussel DJ, Gregor R, Cabantchik ZI: Effects of P-glycoprotein expression on cyclic AMP and volume-activated ion fluxes and conductances in HT-29 colon adenocarcinoma cells. J Cell Physiol 1994, 161:439-446.

22. De Greef CJ, Seher J, Viana F, van Acker K, Eggermont J, Mertens L, Raeymakers L, Droogmans G, Nilius B. Volume-activated chloride currents are not correlated with P-glycoprotein expression. Biochem J 1995, 307:713-718.

23. Waters CM, Horne TP, Arvan M. Regulated uptake of fentanyl, but not alfentanil, by human pulmonary endothelial cells. Anesthesiology 2000, 93:825-831.

24. Wood J, Palmer M, Hewitt J, Urta M, Epp R, Thaell JF: Results of a phase III, double-blind, placebo-controlled trial of megestrol acetate modulation of P-glycoprotein-mediated drug resistance in the first-line management of small-cell lung carcinoma. Br J Cancer 1998, 77:627-631.

25. Beer TW, Rowlands DC, Crocker J: Detection of the multidrug resistance gene (MDR1) in bronchial epithelial cells of hormone and pregnant rats: a comparison to cystic fibrosis mRNA expression. Thorax 1996, 51:526-529.

26. Volm M, Mattern J, Samsel B: Relationship of inherent resistance to doxorubicin, proliferative activity and expression of P-glycoprotein 170, and glutathione S-transferase-pi in human lung tumors. J Cancer Res Clin Oncol 1992, 118:767-774.

27. Volm M, Mattern J, Samsel B: Overexpression of P-glycoprotein and glutathione S-transferase-pi in resistant non-small cell lung carcinomas of smokers. Br J Cancer 1991, 64:700-704.

28. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Briehl J, Mackie J, Grant CE, Alquart KC, Stewart AJ, Kurz EU, Duncan AM, Deele RG: Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992, 258:1650-1654.

29. Lehmann T, Kohler C, Weidauer E, Taege C, Foth H: Expression of MRP1 and related transporters in human lung cells in culture. Toxcology 1991, 167:61-79.

30. Cole SP, Bharadwaj G, Cherrington NJ, Hartley DP, Buist SC, Li N, Klaassen CD: Tissue distribution and chemical induction of multiple drug resistance genes in rats. Drug Metabol Rev 2002, 30:838-844.

31. Sere E, Villard PH, Hever A, Guigal N, Puyou F, Charvet B, Point-Somma H, Lechevalier E, Lacarelle B, Barra Y: Modulation of MDR1 and CYP3A4 expression by dexamethasone: evidence for an inverse regulation in adrenals. Biochem Biophys Res Commun 1998, 252:392-395.

32. Hendriks DE, van Lieshout EM, Risius A, Drieu LA, Drijkoningen A, Holthuis WM, Vossschulte H, Peerlings PA: A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier. Cancer Res 1999, 59:2411-2416.

33. Roering DL, Audi SH, Ahlf SB: Kinetic characterization of P-glycoprotein-mediated efflux of rhodamine 6g in the intact rabbit lung. Drug Metab Dispos 2002, 30:953-958.

34. Edgell MR, Brouwer KR, Brouwer KL: Effect of multidrug resistance modulators on the hepatobiliary disposition of doxorubicin in the isolated perfused rat liver. Cancer Res 1998, 58:3641-3648.

35. Schinkel AH, Mayer U, Wagenaar E, Mol CA, van Deemter L, Stmit J, van de Voort MA, Voordeckers AC, Sprts H, van Tellingen O, Jozlens RMJ, Filter BE, Borst P: Normal viability and altered phospho- 

36. Forbes II: Human airway epithelial cell lines for in vitro drug transport and metabolism studies. Pharm Sci Technol Today 2000, 3:18-27.

37. Eichelbaum M, Fromm MF, Schwab M: Clinical aspects of the MDR1 (ABCB1) gene polymorphism. Ther Drug Monit 2004, 26:180-185.

38. Johansson M, Nordqvist AC, Bogdanovic N, Hjelte L, Schalling M: Polymorphic expression of multidrug resistance mRNA in lung parenchyma of nonpregnant and pregnant rats: a comparison to cystic fibrosis mRNA expression. Biochem Biophys Res Commun 1997, 239:606-611.

39. Sinues B, Fanlo A, Bernal ML, Mayayo E, Bello S, Rubio E, Isla D: MDR-1 C3435T genetic polymorphism and tobacco-related lung cancer. Oncology 2003, 64:183-185.

40. Isla D, Sarries C, Rosell R, Alonso G, Domine M, Taron M, Lopez-Vivas G, Camps C, Botia M, Nuñez L, Sanchez-Ronco M, Sanchez JJ, Lopez-Brea M, Barteto I, Paredes A, Medina B, Artil A, Lianes P: Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol 2004, 15:1194-1203.

41. Zheng H, Zevei A, Schuetz E, Lamba J, McCurry K, Griffith BP, Webber S, Ristic J, Dauber J, Iacono A, Grunwich W, Zaldonis D, McDade K, Zhang J, Burckjt GJ: Tacrolimus dosing in adult lung transplants is related to cytochrome P4503A5 gene polymorphism. J Clin Pharmacol 2004, 44:135-140.

42. ROBY MJ, CHAP, RINTON NJ, Hartley DP, Buist SC, Li N, Klaassen CD: Tissue distribution and chemical induction of multiple drug resistance genes in rats. Drug Metabol Rev 2002, 30:838-844.
human bronchial epithelium. J Histochem Cytochem 1998, 46:513-517.

54. Henke MJ, Ziman GJ, van der Valk P, Izquierdo MA, Schroebers AH, Scheffer GL, van der Groep P, de Haas M, Meijer CJ, Scheper RJ. Tissue distribution of the multidrug resistance protein. Am J Pathol 1996, 148:1237-1247.

55. Kooi M, de Haas M, Scheffer GL, Scheper RJ, van Eijk MJ, Juijn JA, Baas F, Borst P. Analysis of expression of cMOAT (MRP3), MRP1, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res 1997, 57:3357-3347.

56. Wijnholds J, Scheffer GL, van der Valk M, van der Valk P, Beijnen JH, Scheper RJ, Borst P. Multidrug resistance protein 1 protects the oropharyngeal mucosal layer and the testicular tubules against drug-induced damage. J Exp Med 1998, 188:797-808.

57. Thomas GA, Barrand MA, Stewart S, Rabbits PH, Williams ED. Twentyman PR. Expression of the multidrug resistance-associated protein (MRP) gene in human lung tumours and normal tissue as determined by in situ hybridisation. Eur J Cell Biol 1994, 30A:1705-1709.

58. Doubre H, Cesari D, Mairaout A, Benac C, Chantot-Bastaraud S, Dagnon K, Antoine M, Daniel C, Bernaudin JF, Fleury-Feith J. Multidrug resistance-associated protein (MRP1) is overexpressed in DNA aneuploid carcinomatous cells in non-small cell lung cancer (NSCLC). Int J Cancer 2005, 113:568-574.

59. Trompier D, Chang XB, Baratin R, du Moulin J, Hardeman A, Di Pietro A, Baubichon-Cortay H. Verapamil and its derivative trigger apoptosis through glutathione extrusion by multidrug resistance protein (MRP) 1. Cancer Res 2004, 64:4950-4956.

60. Leslie EM, Ito K, Upadhyaya P, Hectt SS, Deele RG, Cole SP. Transport of the beta-O-glucuronide conjugate of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNAL) by the multidrug resistance protein 1 (MRP1). Requirement for glutathione or a non-sulfur-containing analog. J Biol Chem 2001, 276:27846-27854.

61. Kerb R, Hoffmeyer S, Brinkmann U. ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2. Pharmacogenomics 2001, 2:51-64.

62. Saito S, Iida A, Sekine A, Miura TW, Yamamoto M, Sugiyma Y. Transcription factor Nrf2 is required for the constitutive and inducible expression of multidrug resistance-associated protein 1 in mouse embryo fibroblasts. Biochem Biophys Res Commun 2003, 310:824-829.

63. Ramasamy T, Cho CY, Thimmulappa RK, Zhen L, Srisuma SS, Kessler TW, Yamamoto M, Prethrce I, Tuder RM, Biswal S. Genetic ablation of Nrf2 enhances susceptibility to cigarette smoke-induced emphysema in mice. J Clin Invest 2004, 114:1248-1259.

64. Yamamoto T, Yoh K, Kobayashi A, Ishii Y, Kure S, Koyama A, Sakamato T, Sekizawa K, Motohashi H, Yamamoto M. Identification of polymorphisms in the promoter region of the human Nrf2 gene. Biochem Biophys Res Commun 2004, 321:72-79.

65. Wijnholds J, de Lange EC, Scheffer GL, van den Berg DJ, Mol CA, van der Valk M, Schinkel AH, Scheper RJ, Breimer DD, Borst P. Multidrug resistance protein 1 protects the choleodoxus epithelium and contributes to the blood-cerebrospinal fluid barrier. J Clin Invest 2000, 105:279-285.

66. Johnson DR, Finch RA, Lin ZP, Zeiss CJ, Sartorelli AC. The pharmacological phenotype of combined multidrug-resistance mdr1a/1b- and mdr1p-deficient mice. Cancer Res 2001, 61:1469-1476.

67. Muramatsu T, Johnson DR, Finch RA, Johnson LK, Leffert JJ, Lin ZP, Pizzorno G, Sartorelli AC. Age-related differences in vincristine toxicity and biodistribution in wild-type and transporter-deficient mice. Oncol Res 2004, 14:331-343.

68. Bandi N, Kompella UB. Budesonide reduces multidrug resistance-associated protein 1 expression in an airway epithelial cell line (Calu-1). J Pharmacol Exp Ther 2002, 437:9-17.

69. Van der Deen M, Timmer-Bosscha H, Timens W, Postma DS, de Vries EG. Effect of cigarette smoke extract on MRP1 function in bronchial epithelial cells [abstract]. Proc Amer Assoc Cancer Res 2004, 45:A508.

70. Nagayoshi K, Nemoto T, Yokoyama S, Yamashita F, Hashida M. Effect of polycyclic aromatic hydrocarbons on generation and efflux of glutathione conjugates in primary cultured alveolar epithelial cells. Drug Metab Pharmacocinet 2004, 19:407-410.

71. Torky AR, Stehfest E, Vielhewer K, Taege C, Foht H. Immuno-histochemical detection of MRP proteins in human lung cells in culture. Toxicology 2005, 207:437-447.

72. Buchler M, Konig J, Brom M, Kartenbeck J, Spring H, Horie T, Keppler D. cDNA cloning of the hepatocyte canalicular isomorph of the multidrug resistance protein, cMrp, reveals a novel conjugate export pump that is a component in hyperbilirubinemic mutant rats. J Biol Chem 1996, 271:15091-15098.

73. Cui Y, Konig J, Buchholz JK, Spring H, Leier I, Keppler D. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol 1999, 55:929-937.

74. Leier I, Jedlitschky G, Buchholz U, Cole SP, Deele RG, Keppler D. The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates. J Biol Chem 1994, 269:27807-27810.
130. Hickman-Davis J, M. O'Reilly P, Davis IC, Petri-Peterdi J, Davis G, Young KR, Devlin RB, Matalon S; Kiling of Kbsleria pneumoniae by human alveolar macrophages. Am J Physiol Lung Cell Mol Physiol 2002, 282:L1944-L1956.

131. Eiserich JP, Hristova M, Cross CE, Jones AD, Freeman BA, Hallweli B, van der Vliet A; Formation of nitric oxide-derived inflammatory oxidants by myeloperoxidase in neutrophils. Nature 1998, 391:393-397.

132. Punjabi CJ, Laskin JD, Pendino KJ, Goller NL, Durham SK, Laskin DL; Production of nitric oxide synthase and cAMP-mediated Cl- secretion in human normal but not cystic fibrosis bronchial epithelial cells. J Pathol 2000, 190:126-132.

133. Drobnik W, Lindenthal B, Liere R, M., Christiansen WT, Liebisch G, Gies A, Igel M, Borsukova H, Buchler C, Fung-Leung WP, Von Bergmann K, Schmitz G; ATP-binding cassette transporter A1 (ABCA1) affects total body sterol metabolism. Gastroenterology 2001, 120:1203-1211.

134. McNeish J, Allopl RJ, Guyot D, Suri T, Gabel C, Aldinger C, Hoppe KL, Roach RL, Royer LJ, de Wet J, Broccardo C, Chalmers G, Francone OL; High density lipoprotein deficiency and foam cell accumulation in mice with targeted disruption of ATP-binding cassette transporter-1. Proc Natl Acad Sci U S A 2000, 97:4245-4250.

135. Drobnik W, Linder B, Liere R, M., Christiansen WT, Liebisch G, Gies A, Igel M, Borsukova H, Buchler C, Fung-Leung WP, Von Bergmann K, Schmitz G; ATP-binding cassette transporter A1 (ABCA1) affects total body sterol metabolism. Gastroenterology 2001, 120:1203-1211.

136. Yamano G, Funahashi H, Kawamori O, Zhao LX, Ban N, Uchida Y, Morohoshi T, Ogawa J, Shiota S, Inagaki N; ABCA3 is a lamellar body membrane protein in human lung alveolar type II cells. FEBS Lett 2001, 508:221-225.

Publish with BioMed Central and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK

Your research papers will be:
• available free of charge to the entire biomedical community
• peer reviewed and published immediately upon acceptance
• cited in PubMed and archived on PubMed Central
• yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp